Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercebiotech.com

FierceBiotech

Get the latest updates from FierceBiotech directly as they happen.

Follow now 338 followers

Latest posts

Last updated about 2 hours ago

Entry Japan with Clarity, Execute with Confidence

about 2 hours ago

For biopharmaceutical companies, Japan is one of the world’s most important markets...

AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval

about 4 hours ago

AstraZeneca has shared data it believes can rescue anselamimab from a phase...

Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed

about 5 hours ago

Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2...

Boston, China and the future of biotech

about 5 hours ago

Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship...

Chutes & Ladders—Allogene swaps in CMO as new chief exec

about 5 hours ago

After more than eight years at the helm of off-the-shelf CAR-T company...

ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study

about 6 hours ago

Bristol Myers Squibb may have gone big in its pursuit of cereblon...

ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger

about 6 hours ago

Eli Lilly took to the stage at the American Society of Clinical...

Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field

about 6 hours ago

Gilead has abandoned work on the lead rheumatoid arthritis drug from its...

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

about 9 hours ago

Pfizer is paying Innovent $650 million upfront to partner on cancer drug...

FDA extends Beren’s rare disease review after info request, further stretching saga

1 day ago

The FDA has delayed its approval decision on Beren Therapeutics’ rare disease...

Icon ends internal accounting investigation, finds it overstated revenue in prior years

1 day ago

Irish CRO Icon has concluded its investigation into its accounting practices and...

Hoth Therapeutics’ pivot to AI in space sees stock rocket after rebrand

1 day ago

Hoth Therapeutics’ search for salvation in the stars appears to have been...